GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (NYSE:ABBV) » Definitions » Cyclically Adjusted Price-to-FCF

AbbVie (AbbVie) Cyclically Adjusted Price-to-FCF : 17.13 (As of Apr. 27, 2024)


View and export this data going back to 2012. Start your Free Trial

What is AbbVie Cyclically Adjusted Price-to-FCF?

As of today (2024-04-27), AbbVie's current share price is $159.62. AbbVie's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $9.32. AbbVie's Cyclically Adjusted Price-to-FCF for today is 17.13.

The historical rank and industry rank for AbbVie's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

ABBV' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 15.05   Med: 18.41   Max: 23.97
Current: 17.95

During the past years, AbbVie's highest Cyclically Adjusted Price-to-FCF was 23.97. The lowest was 15.05. And the median was 18.41.

ABBV's Cyclically Adjusted Price-to-FCF is ranked better than
71.91% of 324 companies
in the Drug Manufacturers industry
Industry Median: 32.655 vs ABBV: 17.95

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

AbbVie's adjusted free cash flow per share data for the three months ended in Dec. 2023 was $2.561. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $9.32 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


AbbVie Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for AbbVie's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Cyclically Adjusted Price-to-FCF Chart

AbbVie Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 18.76 19.53 19.55 16.63

AbbVie Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.55 18.65 15.26 16.23 16.63

Competitive Comparison of AbbVie's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, AbbVie's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbbVie's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AbbVie's Cyclically Adjusted Price-to-FCF falls into.



AbbVie Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

AbbVie's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=159.62/9.32
=17.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, AbbVie's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=2.561/129.4194*129.4194
=2.561

Current CPI (Dec. 2023) = 129.4194.

AbbVie Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 0.303 99.695 0.393
201406 0.979 100.560 1.260
201409 0.998 100.428 1.286
201412 -0.453 99.070 -0.592
201503 0.896 99.621 1.164
201506 1.051 100.684 1.351
201509 1.219 100.392 1.571
201512 1.107 99.792 1.436
201603 1.235 100.470 1.591
201606 1.095 101.688 1.394
201609 0.818 101.861 1.039
201612 0.878 101.863 1.116
201703 1.252 102.862 1.575
201706 1.173 103.349 1.469
201709 1.962 104.136 2.438
201712 1.496 104.011 1.861
201803 1.583 105.290 1.946
201806 1.751 106.317 2.131
201809 2.800 106.507 3.402
201812 2.178 105.998 2.659
201903 1.962 107.251 2.368
201906 1.583 108.070 1.896
201909 2.968 108.329 3.546
201912 2.093 108.420 2.498
202003 2.487 108.902 2.956
202006 1.768 108.767 2.104
202009 3.164 109.815 3.729
202012 2.569 109.897 3.025
202103 2.642 111.754 3.060
202106 2.644 114.631 2.985
202109 4.343 115.734 4.857
202112 2.746 117.630 3.021
202203 2.669 121.301 2.848
202206 2.738 125.017 2.834
202209 4.181 125.227 4.321
202212 4.051 125.222 4.187
202303 2.262 127.348 2.299
202306 3.468 128.729 3.487
202309 4.153 129.860 4.139
202312 2.561 129.419 2.561

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AbbVie  (NYSE:ABBV) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


AbbVie Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of AbbVie's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AbbVie (AbbVie) Business Description

Industry
Address
1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Executives
Nicholas Donoghoe officer: SVP, Enterprise Innovation 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Susan E Quaggin director 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jennifer L. Davis director 1 PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Richard A Gonzalez officer: Chairman of the Board and CEO 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Elaine K. Sorg officer: Sr. V.P., U.S. Commercial Ops. 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Perry C Siatis officer: EVP, GC and Secretary 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jeffrey Ryan Stewart officer: SVP, US Commercial Operations 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Kevin K Buckbee officer: SVP, Controller 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Scott T Reents officer: SVP, Chief Financial Officer 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Azita Saleki-gerhardt officer: SVP, Operations 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Carrie C Strom officer: SVP & Pres Global Allerg Aesth 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Roxanne S Austin director 200 N SEPULVEDA BLVD, PO BOX 956 MS ES/001/A102, EL SEGUNDO CA 90245
Timothy J. Richmond officer: EVP, Chief HR Officer 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Michael Severino officer: EVP, R&D and CSO 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Henry O Gosebruch officer: Chief Strategy Officer 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092

AbbVie (AbbVie) Headlines

From GuruFocus

Abbvie Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Q4 2022 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2022 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Abbvie Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024